Sunshine Biopharma Inc. 8-K

What Happened

• Sunshine Biopharma Inc. (SBFM) announced a best-efforts registered offering that closed on May 19, 2026. The company sold 11,160,000 Common Units and 840,000 Pre‑Funded Units under an effective Form S-1 declared effective May 18, 2026.
• Each Common Unit was sold at $0.50 and each Pre‑Funded Unit at $0.49999. Gross proceeds were approximately $6.0 million, before placement agent fees and other offering expenses. Aegis Capital Corp. served as placement agent under a Placement Agent Agreement.

Key Details

• Securities sold: 11,160,000 Common Units (each = 1 share + 2 Series C Warrants) and 840,000 Pre‑Funded Units (each = pre‑funded warrant exercisable for 1 share + 2 Series C Warrants).
• Pricing and warrants: Common Unit price $0.50; Pre‑Funded Unit price $0.49999; Pre‑Funded Warrants exercisable immediately at $0.00001; Series C Warrants exercisable immediately at $0.50, expire five years from issuance.
• Anti-dilution feature: Series C exercise price may be reduced following a stock split/dividend/recapitalization-type event to as low as $0.25 (50% of initial price), subject to Nasdaq stockholder approval and limited to one such adjustment.
• Placement agent compensation: Aegis received 7% of the public offering price plus a non-accountable expense allowance of 2%; the company also reimbursed certain accountable expenses. The company issued press releases on May 18 and May 19, 2026 announcing pricing and closing.

Why It Matters

• This filing documents a capital raise that provides Sunshine Biopharma with immediate cash (about $6M gross) to fund operations, programs, or other corporate needs. Net proceeds will be lower after the placement agent fee (7%), the 2% expense allowance, and reimbursed expenses.
• Investors should note potential dilution: the offering issued shares plus warrants that can convert into additional shares (including pre‑funded warrants already exercisable), which could increase shares outstanding if exercised. The Series C warrants contain limited anti‑dilution protection that may reduce their exercise price in certain corporate actions but requires Nasdaq approval to be effective.